Table 4 Immune reconstitution within 1 year post-transplantation (absolute value)
| Â | Â | CD3+ | CD3+CD4+ | CD3+CD8+ | CD19+ | CD3-CD56+ |
|---|---|---|---|---|---|---|
Months after allo-HSCT | Â | Mean absolute value (109/L, range) | Mean absolute value (109/L, range) | Mean absolute value (109/L, range) | Mean absolute value (109/L, range) | Mean absolute value (109/L, range) |
1st(N=202) | Sorafenib group | 0.450 (0.025–1.218) | 0.086 (0.007–0.239) | 0.296 (0.009–0.938) | 0.009 (0.000–0.049) | 0.137 (0.024–0.336) |
Control group | 0.621 (0.047–1.515) | 0.085 (0.007–0.144) | 0.451 (0.032–1.392) | 0.010 (0.001–0.035) | 0.193 (0.079–0.378) | |
P | 0.267 | 0.966 | 0.262 | 0.870 | 0.159 | |
3rd(N=188) | Sorafenib group | 0.985 (0.191–2.835) | 0.182 (0.030–0.470) | 0.681 (0.077–2.446) | 0.059 (0.000–0.336) | 0.323 (0.026–0.910) |
Control group | 1.294 (0.510–3.779) | 0.209 (0.057–0.485) | 0.977 (0.183–3.285) | 0.039 (0.000–0.102) | 0.275 (0.102–0.534) | |
P | 0.261 | 0.501 | 0.244 | 0.416 | 0.519 | |
6th(N=165) | Sorafenib group | 1.273 (0.398–2.823) | 0.257 (0.105–0.674) | 0.863 (0.202–2.633) | 0.082 (0.002–0.307) | 0.272 (0.095–0.595) |
Control group | 1.228 (0.322–2.925) | 0.232 (0.105–0.347) | 0.907 (0.122–2.500) | 0.076 (0.007–0.226) | 0.246 (0.098–0.529) | |
P | 0.858 | 0.824 | 0.587 | 0.557 | 0.842 | |
9th(N=152) | Sorafenib group | 1.394 (0.211–3.714) | 0.211 (0.058–0.458) | 1.075 (0.115–3.486) | 0.111 (0.001–0.344) | 0.281 (0.025–1.069) |
Control group | 1.236 (0.356–3.702) | 0.234 (0.055–0.546) | 0.899 (0.209–3.159) | 0.137 (0.002–0.478) | 0.309 (0.052–0.903) | |
P | 0.542 | 0.575 | 0.469 | 0.442 | 0.747 | |
12th(N=141) | Sorafenib group | 1.626 (0.309–3.906) | 0.293 (0.066–0.743) | 1.220 (0.222–3.630) | 0.184 (0.002–0.558) | 0.271 (0.010–0.755) |
Control group | 1.448 (0.536–2.735) | 0.315 (0.102–0.764) | 1.025 (0.333–2.494) | 0.229 (0.003–1.208) | 0.370 (0.058–1.075) | |
P | 0.459 | 0.627 | 0.410 | 0.448 | 0.141 |